Treatment of Patients With Advanced Rectum Cancer With Capecitabine and Oxaliplatin Before, Under and After Radiation and With Adding Cetuximab to K-RAS Wild-type Patients

Treatment of Patient With Advanced Rectum Cancer With Capecitabine and Oxaliplatin Before Under and After Radiation and With Adding Cetuximab to K_RAS Wild-type Patients.

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00964457

Enrollment

Registered

2009-08-25

Start date

2009-08-31

Completion date

2017-07-31

Last updated

2009-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectum Cancer

Keywords

cetuximab, rectum cancer, radiation, MRI

Brief summary

response rate to adding cetuximab, oxaliplatin and capecitabine to radiation for advanced rectum cancer

Detailed description

Dynamic MRI will be used to monitor the effect of the treatment and will be compared to pathologic results.

Interventions

DRUGcetuximab

cetuximab 500mg per meter square every second week

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* advanced rectum cancer

Exclusion criteria

* prior radiation

Design outcomes

Primary

Measure	Time frame
response rate	3 years

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026